Clinical trials: psoriasis
Psoriasis Vulgaris
A Plaque Test Comparing the Anti-psoriatic Effect of Marketed Products for Topical Use for Psoriasis Vulgaris
The purpose of the study is to compare the anti-psoriatic effect of marketed products with Daivobet® ointment in a plaque test
- Trial name
- NCT00845481
- Testing
- Daivobet® ointment, Betnovat® ointment, Diprosalic ointment
- Where
- France
- Volunteers
- 24 people
- Sponsor
- LEO Pharma
Psoriasis
Elocon vs Fluticasone in Localized Psoriasis (P03197)
This is an open-label, randomized, parallel-group clinical study. The primary objective is to assess the difference in response rate between mometasone furoate cream 0.1% (once daily) vs fluticasone propionate cream 0.05% (twice…
- Trial name
- NCT00763529
- Testing
- Mometasone, Fluticasone
- Volunteers
- 245 people
- Sponsor
- Organon and Co
Moderate-to-severe Plaque Psoriasis
Real-World Safety and Effectiveness of Sotyktu (Deucravacitinib) in Patients With Moderate-to-Severe Plaque Psoriasis in Korea
The purpose of this observational study is to describe the safety and effectiveness of deucravacitinib in participants in Korea that have been diagnosed with moderate-to-severe plaque psoriasis.
- Trial name
- NCT06258668
- Testing
- Deucravacitinib
- Where
- 2 sites in South Korea
- Volunteers
- 505 people
- Sponsor
- Bristol-Myers Squibb
Psoriatic Arthritis
Safety and Efficacy of Adalimumab in Patients With Moderate to Severely Active Psoriatic Arthritis
The purpose of the study is to assess the long-term safety and clinical efficacy of adalimumab in treatment of moderate to severely active psoriatic arthritis
- Trial name
- NCT00195689
- Testing
- Human anti-TNF monoclonal antibody/adalimumab
- Where
- United States
- Volunteers
- 400 people
- Sponsor
- Abbott
Plaque Psoriasis.
ASIS for Enbrel in Plaque Psoriasis
AUTOMATIC SUBDERMAL INJECTOR SYSTEM (ASIS) Corporation has developed and patented the only automatic injection system for delivery of injectable products to the optimum spot, just outside of the fascia, which exists subdermally…
- Trial name
- ASISinPP (NCT02112097)
- Testing
- Gadolinium, Efficacy of Enbrel subcutaneously at Week 12, Efficacy of Enbrel subcutaneously at Week 24
- Where
- 2 sites in United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- ASIS Corporation
Palmoplantar Pustulosis
A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in Adults With Palmoplantar Pustulosis
A study to evaluate the efficacy and safety, and pharmacokinetic (PK) profile of multiple doses of imsidolimab (ANB019) in adults with palmoplantar pustulosis (PPP)
- Trial name
- POPLAR (NCT03633396)
- Testing
- Imsidolimab
- Where
- 39 sites in United States, Canada and 2 more
- Volunteers
- 59 people
- Sponsor
- Vanda Pharmaceuticals
Psoriasis Vulgaris
Evaluation of DD-25 Topical Cream for the Treatment of Psoriasis Vulgaris : Proof of Concept Study
The purpose of this study is to determine the efficacy of DD-25, a new topical drug, on plaque Psoriasis Vulgaris. The study will include subjects at plaque stage from 5-20% body area involvement.
- Trial name
- NCT01702324
- Testing
- DD-25
- Where
- Israel
- Volunteers
- 30 people
- Sponsor
- Fortuderm Ltd.
Psoriasis
A Study Evaluating The Efficacy And Safety Of CP-690,550 In Asian Subjects With Moderate To Severe Plaque Psoriasis
The primary objective of this study is to compare the efficacy of CP-690,550 (5 mg BID and 10 mg BID) versus placebo for the reduction in severity of plaque psoriasis after 16 weeks of treatment in Asian subjects with moderate to…
- Trial name
- NCT01815424
- Testing
- CP-690,550
- Where
- 24 sites in China, South Korea and 1 more
- Volunteers
- 266 people
- Sponsor
- Pfizer
Psoriasis
Study of Therapeutic Options for Subjects Discontinuing Efalizumab and Experiencing Disease Recurrence
This is a pilot investigational study of the appropriate therapeutic regimens to treat subjects experiencing inflammatory recurrence (rebound) of psoriatic disease upon discontinuation of efalizumab therapy and of the biological…
- Trial name
- NCT01079988
- Testing
- Cyclosporins, Retinoids, Systemic corticosteroids
- Volunteers
- 41 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Atopic Dermatitis (AD), Psoriasis
A Clinical Evaluation of Marula-Derived Ceramide Cream on Skin Barrier Function Enhancement
Previously, the investigators have demonstrated in vitro the excellent efficacy of marula oil-derived ceramide NPs in enhancing skin barrier function.
- Conditions
- Atopic Dermatitis (AD), Psoriasis, Acne Vulgaris, Contact Dermatitis
- Trial name
- NCT07066150
- Testing
- Apply a cream containing 0.05% marula oil-derived ceramide NPs
- Where
- China
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Shanghai Chicmax Cosmetic Co., Ltd.
Moderate Plaque Psoriasis
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body)
Psoriasis is a long-term skin disease which causes red, itchy, scaly patches most commonly on the knees, elbows, scalp, and torso (chest, back, and abdomen).
- Trial name
- IMMpactful (NCT06333860)
- Testing
- Risankizumab, Deucravacitinib
- Where
- 88 sites in United States, Australia and 10 more
- Volunteers
- 393 people
- Sponsor
- AbbVie
Psoriasis
A Study to Assess Safety and Efficacy of Risankizumab Using a New Formulation in Participants With Moderate to Severe Plaque Psoriasis
The primary objective of this study was to evaluate the safety and efficacy of risankizumab (150 mg/mL) administered by prefilled syringe (PFS) for the treatment of adult participants with moderate to severe plaque psoriasis.
- Trial name
- NCT03875482
- Testing
- Risankizumab
- Where
- 43 sites in United States, Puerto Rico
- Volunteers
- 157 people
- Sponsor
- AbbVie
Arthritis, Rheumatoid, Crohn Disease
A Long-term Safety Study of Infliximab (Remicade)
This is a study evaluating the long-term safety of infliximab (Remicade)
- Conditions
- Arthritis, Rheumatoid, Crohn Disease, Psoriasis
- Trial name
- NCT00261976
- Testing
- Infliximab (Remicade)
- Where
- 205 sites in United States, Argentina and 17 more
- Volunteers
- 2,971 people
- Sponsor
- Centocor, Inc.
Chronic Plaque Psoriasis
TRUST Study: Raptiva ® in Hand & Foot Psoriasis
To evaluate the safety and efficacy of Raptiva ® compared with placebo to control chronic moderate to severe plaque psoriasis involving the hands and/or feet scoring Physician's Global Assessment (PGA - H\&F) greater-than or…
- Trial name
- TRUST (NCT00739882)
- Testing
- Efalizumab - anti CD11a recombinant human monoclonal antibody
- Where
- Austria
- Volunteers
- 76 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Chronic Plaque Psoriasis, Moderate to Severe Chronic Plaque Psoriasis
A Study With a Initial Treatment Period Followed by a Randomized-withdrawal Period to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis
Phase 3 study to compare the efficacy of bimekizumab versus placebo in the treatment of subjects with moderate to severe chronic plaque psoriasis.
- Conditions
- Chronic Plaque Psoriasis, Moderate to Severe Chronic Plaque Psoriasis, Psoriatic Arthritis
- Trial name
- BE READY (NCT03410992)
- Testing
- Bimekizumab
- Where
- 77 sites in United States, Australia and 7 more
- Volunteers
- 435 people
- Sponsor
- UCB Biopharma SRL
Plaque Psoriasis
A Proof of Concept Study With 0.5% Roflumilast Cream in Patients With Mild to Moderate Plaque Psoriasis
The aim of this proof of concept study is to show the safety and efficacy of 0.5 % dermal roflumilast cream in the treatment of plaque psoriasis in adults.
- Trial name
- NCT00746434
- Testing
- Roflumilast cream
- Sponsor
- AstraZeneca
Arthritis, Psoriatic
A Study of RO5310074 in Patients With Psoriatic Arthritis
This randomized, double-blind. placebo-controlled study will assess the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple doses of RO5310074 in patients with psoriatic arthritis who have or have had an…
- Trial name
- NCT01199809
- Testing
- RO5310074
- Where
- 9 sites in United States, Australia and 1 more
- Volunteers
- 19 people
- Sponsor
- Hoffmann-La Roche
Psoriatic Arthritis
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants With Active Psoriatic Arthritis
The purpose of the study is to compare the efficacy of bimekizumab versus risankizumab after 16 weeks of treatment in study participants with active psoriatic arthritis (PsA).
- Trial name
- NCT06624228
- Testing
- Bimekizumab, Risankizumab
- Where
- 127 sites in United States, Australia and 9 more
- Volunteers
- 553 people
- Sponsor
- UCB Biopharma SRL
Psoriasis
Paired Psoriasis Lesion, Comparative, Study to Evaluate MOL4239 in Psoriasis
The purpose of this study is to determine whether MOL4239 is effective in adult subjects with mild to moderate plaque psoriasis by comparing two target lesions in which each subject will apply MOL4239 ointment to one target…
- Trial name
- NCT01826201
- Testing
- MOL4239
- Where
- 3 sites in United States
- Volunteers
- 21 people
- Sponsor
- Moleculin, LLC
Psoriasis
A Study of Safety and Efficacy Comparing ABT-874 Versus Methotrexate in Subjects With Moderate to Severe Plaque Psoriasis
This study is being conducted to compare the efficacy of ABT-874 versus Methotrexate in subjects with moderate to severe plaque psoriasis.
- Trial name
- NCT00679731
- Testing
- ABT-874, Methotrexate
- Where
- 43 sites in Austria, Belgium and 12 more
- Volunteers
- 317 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.